C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping

被引:23
作者
Nielsen, EW [1 ]
Mollnes, TE
Harlan, JM
Winn, RK
机构
[1] Nordland Hosp, Dept Anesthesiol, N-8092 Bodo, Norway
[2] Univ Tromso, Bodo, Norway
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Oslo, Natl Hosp, Inst Immunol, Oslo, Norway
[5] Univ Washington, Dept Med, Seattle, WA USA
[6] Univ Washington, Dept Physiol Biophys, Seattle, WA USA
关键词
D O I
10.1046/j.1365-3083.2002.01173.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Both C1-inhibitor (C1-INH) and antibodies against the CD18 adhesion molecule have been shown to reduce ischaemia-reperfusion injuries. The objective of this study was to investigate the effect of increased ischaemia times and to determine whether inhibiting C1 or blocking the CD18 function was protective in skeletal muscle ischaemia-reperfusion injury after aortic cross-clamping. Materials and methods: BALB/c mice were subjected to aortic cross-clamping below the renal artery for 60, 75 or 105 min, followed by 3 h of reperfusion. Two-thirds of a total dose of anti-CD18 antibody (40 mg/kg) or human C1-INH (1000 IU/kg) was given by intraperitoneal injection before ischaemia and one-third immediately after the clamping. Creatine kinase (CK) in the plasma was used as an indicator of muscle injury severity. Results: There was a consistent rise in the plasma CK concentration proportional to the length of ischaemia (P < 0.0005). C1-INH treatment significantly (P = 0.012) reduced the plasma CK for the ischaemia times of 75 and 105 min. The anti-CD18 antibody did not have any effect, as demonstrated by the CK values that were similar to controls (P = 0.836). Conclusion: The data support a beneficial role for C1-INH in the treatment of ischaemia-reperfusion injuries of skeletal muscles.
引用
收藏
页码:588 / 592
页数:5
相关论文
共 31 条
[1]  
*ARZN DTSCH ARZT, 2001, DTSCH ARZTEBLATT, V97, pA1016
[2]   Therapeutic inhibition of the complement system. Y2K update [J].
Asghar, SS ;
Pasch, MC .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :E63-E82A
[3]   Double-blind, randomized trial of an Anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction - Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study [J].
Baran, KW ;
Nguyen, M ;
McKendall, GR ;
Lambrew, CT ;
Dykstra, G ;
Palmeri, ST ;
Gibbons, RJ ;
Borzak, S ;
Sobel, BE ;
Gourlay, SG ;
Rundle, AC ;
Gibson, CM ;
Barron, HV .
CIRCULATION, 2001, 104 (23) :2778-2783
[4]   C1 inhibitor potentiates the protective effect of organ preservation solution on endothelial cells during cold storage [J].
Bergamaschini, L ;
Gatti, S ;
Caccamo, L ;
Prato, P ;
Latham, L ;
Trezza, P ;
Maggioni, M ;
Gobbo, G ;
Fassati, LR .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :939-941
[5]   Effects of low dose-intra-arterial monoclonal antibodies to ICAM-1 and CD11/CD18 on local and systemic consequences of ischaemia-reperfusion injury in skeletal muscle [J].
Breidahl, AF ;
Hickey, MJ ;
Stewart, AG ;
Hayward, PG ;
Morrison, WA .
BRITISH JOURNAL OF PLASTIC SURGERY, 1996, 49 (04) :202-209
[6]  
Buerke M, 1998, J PHARMACOL EXP THER, V286, P429
[7]   Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits [J].
Buerke, M ;
Schwertz, H ;
Seitz, W ;
Meyer, J ;
Darius, H .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :5375-5380
[8]   A murine skeletal muscle ischemia-reperfusion injury model: differential pathology in BALB/c and DBA/2N mice [J].
Carter, WO ;
Bull, C ;
Bortolon, E ;
Yang, L ;
Jesmok, GJ ;
Gundel, RH .
JOURNAL OF APPLIED PHYSIOLOGY, 1998, 85 (05) :1676-1683
[9]  
CORNEJO CJ, 1997, ADHESION MOL HLTH DI, P483
[10]  
de Zwaan C, 2001, J AM COLL CARDIOL, V37, p312S